Abstract
To evaluate the chemotherapeutic efficacy of J591 fabricated poly(d,l)-lactic-co-glycolic acid (PLGA) nanoparticles containing paclitaxel (Ab-PTX-NP) in vitro in PSMA (prostate specific membrane antigen) expressing prostate cancer cells, increase the solubility, bioavailability, circulation time, and limit systemic toxicity to achieve the maximum curative effect accompanied by controlled dosing, we formulated Ab-PTX-NP. Physicochemical characterizations such as Field emission scanning electron microscopy, Transmission electron microscopy, and Atomic force microscopy revealed that the particles were smooth-surfaced, with homogeneous distribution of drug within the particles and size were in the nano range. The encapsulation efficiency of Ab-PTX-NP was found to be 70.85%. This study acknowledges the effectiveness of Ab-PTX-NP in vitro, which displays elevated cellular cytotoxicity and internalization, maximum apoptosis (74.1%) in PSMA-abundant LNCaP cells, in comparison to PSMA negative PC3 cells. Pharmacokinetic data revealed the bioavailability of paclitaxel upon i.v. administration in the systemic circulation of male Balb/c mice. Herein, J591 was maneuvered in a neoteric way to carry the prepared chemotherapeutic nanoparticles directly to the affected prostate cancer cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
